The global Aortic Stents Grafts Market is projected to grow at a CAGR of 7.2% from 2024 to 2031. The market value is expected to rise from XX USD in 2024 to YY USD by 2031. North America currently dominates the market, with key metrics indicating a growing demand for minimally invasive aortic aneurysm treatments. The market is experiencing significant growth due to increasing prevalence of aortic aneurysms, technological advancements in stent graft designs, and rising adoption of endovascular procedures.
Market Trend: Increasing Adoption of Fenestrated and Branched Stent Grafts
The aortic stent grafts industry is seeing a considerable shift towards the use of fenestrated and branching stent grafts. These advanced devices are intended to treat difficult aortic aneurysms, particularly those that affect the renal and visceral arteries. The necessity for more physically complex situations and a desire to broaden the applicability of endovascular aneurysm repair (EVAR) are driving this trend. Fenestrated and branching stent grafts have been proven in studies to successfully treat up to 85% of juxtarenal aneurysms that were previously unsuitable for routine EVAR, resulting in a 30% reduction in open surgical operations for complicated aortic aneurysms.
Market Driver: Growing Prevalence of Aortic Aneurysms in Aging Populations
The rising occurrence of aortic aneurysms, particularly in older populations, is a major driver of the aortic stents grafts industry. According to current epidemiological studies, the incidence of abdominal aortic aneurysms (AAA) in those over 65 ranges between 4% and 8%, with the risk increasing dramatically with age. This incidence is likely to rise even more as the world's population ages. For example, in the United States, the number of persons aged 65 and up is expected to nearly double from 52 million in 2018 to 95 million by 2060, potentially resulting in a 40% increase in AAA cases. This demographic shift, combined with enhanced screening programs, is driving rising demand for aortic stent grafts as a preferred treatment.
Market Restraint: High Costs and Reimbursement Challenges
Despite the clinical benefits, the high prices of aortic stent grafts and accompanying operations present a substantial barrier to market growth. The average cost of an endovascular aneurysm repair (EVAR) operation with stent grafts is between $30,000 to $40,000, which is significantly higher than traditional open surgical treatment. Furthermore, payment regulations in many countries do not completely cover these treatments, placing financial strain on individuals and healthcare systems. A recent healthcare economic analysis found that roughly 25% of eligible patients in underdeveloped countries avoid EVAR operations due to cost concerns, instead opting for more risky open surgical alternatives or no therapy at all.
The Abdominal Aortic Stent Grafts segment dominates the Aortic Stents Grafts market:
Abdominal Aortic Stent Grafts have the biggest market share in the aortic stent grafts business, owing to the higher prevalence of abdominal aortic aneurysms (AAA) compared to thoracic aneurysms. This segment's dominance is related to the extensive use of endovascular aneurysm repair (EVAR) procedures for AAA therapy, as well as continuing technological advancements in stent graft design.
Recent advances in abdominal aortic stent grafts have centred on increasing long-term durability and anatomical application. For example, the introduction of low-profile delivery devices has allowed for the treatment of patients with smaller access channels, potentially boosting the eligible patient group by 30%. Furthermore, next generation stent grafts with active fixation mechanisms have demonstrated a 50% reduction in type I endoleaks, a typical consequence of EVAR, resulting in better long-term results.
The hospital segment of the abdominal aortic stent grafts market has experienced particularly rapid expansion. With the growing complexity of EVAR procedures and the necessity for specialised imaging equipment, hospitals continue to be the principal site for these interventions. According to studies, high-volume hospital centres that execute more than 50 EVAR procedures per year had 25% lower death rates than low-volume centres, leading to the centralisation of these treatments in specialised institutions. This tendency has resulted in large expenditures in hybrid operating rooms capable of performing advanced endovascular operations, reinforcing the hospital segment's market dominance.
Dominating Region: North America leads the global Aortic Stents Grafts market
North America currently has the greatest share of the worldwide Aortic Stents Grafts market, owing to its advanced healthcare infrastructure, high acceptance rate of minimally invasive technologies, and high prevalence of aortic aneurysms in the elderly population.
Several reasons contribute to the region's dominance, including solid reimbursement policies for endovascular operations, the presence of important market participants, and widespread knowledge of the benefits of EVAR among patients and healthcare providers. The United States, in particular, has experienced a continuous increase in EVAR procedures, with the most recent data indicating that more than 80% of qualifying AAA repairs are being performed endovascularly.
Recent advances in the North American market include the FDA's approval of innovative stent graft designs geared to difficult anatomies. These advancements have extended the curable patient pool, with some estimates indicating a 20% rise in EVAR eligibility over the last five years.
Key data demonstrate the region's market strength: over 200,000 persons in the United States are diagnosed with abdominal aortic aneurysms each year, with roughly 15,000 deaths caused by AAA ruptures. The implementation of screening programs, particularly for high-risk individuals, has resulted in earlier detection and management, increasing demand for aortic stent grafts.
The Canadian market has also grown significantly, because to recent government measures to cut wait times for vascular procedures. Over the last decade, the number of EVAR procedures in the country has increased by 40%, indicating a growing preference for less invasive techniques to aortic aneurysm care.
The Aortic Stents Grafts market is characterised by fierce competition among leading competitors, with an emphasis on technological innovation and clinical evidence development. Market leaders are making significant investments in R&D to provide next-generation stent grafts with increased deliverability, durability, and adaptation to complicated anatomies. Mergers and acquisitions have been an important strategy for corporations looking to diversify their product portfolios and increase their market position.
Leading firms in the market have been working to establish comprehensive aortic solution portfolios that address a wide range of anatomical issues. For example, one large manufacturer reported a 30% rise in aortic stent graft revenue after introducing a new low-profile device tailored for patients with narrow access arteries.
In terms of market share, the top five corporations control almost 75% of the global market. These firms have built excellent partnerships with key opinion leaders and vascular surgical centres, resulting in increased acceptance of their solutions. Recent financial reports show that the aortic stent graft market has been a key growth driver for these companies, with some showing double-digit growth in their endovascular therapy business divisions.
In the future, the market is projected to experience more competition from rising competitors, particularly in specialised niches like branching and fenestrated grafts for complicated aneurysms. The future prognosis predicts a shift towards more personalised stent graft treatments, with a focus on patient-specific designs made possible by better imaging and 3D printing technologies.
The market for Aortic Stents Grafts is expected to rise further in the future years, owing to technical improvements and increased indications for endovascular repair. The incorporation of artificial intelligence and machine learning into preoperative planning and intraoperative supervision is predicted to improve results and boost use of EVAR procedures.
The development of bioabsorbable stent grafts is a particularly interesting trend to follow. Recent biomaterials research shows promise in developing stent grafts that can give initial support while progressively absorbing, allowing for natural artery repair. This method could potentially alleviate some of the long-term issues associated with permanent implants, such as material fatigue and endoleaks.
Medtronic plc
Cook Medical
W. L. Gore & Associates
Terumo Corporation
Cardinal Health (Cordis)
Endologix LLC
Lombard Medical
MicroPort Scientific Corporation
Jotec GmbH (CryoLife, Inc.)
Vascutek Ltd. (Terumo Aortic)
Medtronic plc got FDA approval in August 2023 for a new thoracic stent graft system designed to treat blunt thoracic aortic injuries, boosting its portfolio of aortic trauma cases.
March 2023: W. L. Gore & Associates announced the conclusion of patient enrolment in a pivotal clinical trial for their next-generation abdominal aortic stent transplant, which incorporates a unique sealing technology.
1. INTRODUCTION
1.1. Market Definitions & Study Assumptions
1.2. Market Research Scope & Segment
1.3. Research Methodology
2. EXECUTIVE SUMMARY
2.1. Market Overview & Insights
2.2. Segment Outlook
2.3. Region Outlook
3. COMPETITIVE INTELLIGENCE
3.1. Companies Financial Position
3.2. Company Benchmarking -- Key Players
3.3. Market Share Analysis -- Key Companies
3.4. Recent Companies Key Activities
3.5. Pricing Analysis
3.6. SWOT Analysis
4. COMPANY PROFILES (Key Companies list by Country) (Premium)
5. COMPANY PROFILES
5.1. Medtronic plc
5.2. Cook Medical
5.3. W. L. Gore & Associates
5.4. Terumo Corporation
5.5. Cardinal Health (Cordis)
5.6. Endologix LLC
5.7. Lombard Medical
5.8. MicroPort Scientific Corporation
5.9. Jotec GmbH (CryoLife, Inc.)
5.10. Vascutek Ltd. (Terumo Aortic) (*LIST NOT EXHAUSTIVE)
6. MARKET DYNAMICS
6.1. Market Trends
6.1.1. Increasing Adoption of Fenestrated and Branched Stent Grafts
6.1.2. Integration of AI and Machine Learning in EVAR Planning
6.1.3. Development of Bioabsorbable Stent Grafts
6.2. Market Drivers
6.2.1. Growing Prevalence of Aortic Aneurysms in Aging Populations
6.2.2. Technological Advancements in Stent Graft Designs
6.2.3. Rising Adoption of Endovascular Procedures
6.3. Market Restraints
6.3.1. High Costs and Reimbursement Challenges
6.3.2. Complications Associated with EVAR Procedures
6.4. Market Opportunities
6.5. Porter's Five Forces Analysis
6.5.1. Threat of New Entrants
6.5.2. Bargaining Power of Buyers/Consumers
6.5.3. Bargaining Power of Suppliers
6.5.4. Threat of Substitute Products
6.5.5. Intensity of Competitive Rivalry
6.6. Supply Chain Analysis
6.7. Value Chain Analysis
6.8. Trade Analysis
6.9. Pricing Analysis
6.10. Regulatory Analysis
6.11. Patent Analysis
6.12. SWOT Analysis
6.13. PESTLE Analysis
7. BY PRODUCT TYPE (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
7.1. Abdominal Aortic Stent Grafts
7.1.1. Infrarenal Stent Grafts
7.1.2. Pararenal Stent Grafts
7.1.3. Fenestrated Stent Grafts
7.2. Thoracic Aortic Stent Grafts
7.2.1. Standard Thoracic Stent Grafts
7.2.2. Branched Thoracic Stent Grafts
8. BY END-USER (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
8.1. Hospitals
8.2. Ambulatory Surgery Centers
8.3. Others
9. REGION (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
9.1. North America
9.1.1. United States
9.1.2. Canada
9.1.3. Mexico
9.2. South America
9.2.1. Brazil
9.2.2. Argentina
9.2.3. Rest of South America
9.3. Europe
9.3.1. Germany
9.3.2. United Kingdom
9.3.3. France
9.3.4. Italy
9.3.5. Spain
9.3.6. Russia
9.3.7. Rest of Europe
9.4. Asia-Pacific
9.4.1. China
9.4.2. Japan
9.4.3. India
9.4.4. Australia
9.4.5. South Korea
9.4.6. Rest of Asia-Pacific
9.5. Middle-East
9.5.1. UAE
9.5.2. Saudi Arabia
9.5.3. Turkey
9.5.4. Rest of Middle East
9.6. Africa
9.6.1. South Africa
9.6.2. Egypt
9.6.3. Rest of Africa
*NOTE: All the regions mentioned in the scope will be provided with (MARKET SIZE/VALUE (US$ Mn), SHARE (%), MARKET FORECAST (%), YOY GROWTH (%)-- 2020-2031)
By Product Type:
Abdominal Aortic Stent Grafts
Infrarenal Stent Grafts
Pararenal Stent Grafts
Fenestrated Stent Grafts
Thoracic Aortic Stent Grafts
Standard Thoracic Stent Grafts
Branched Thoracic Stent Grafts
By End-User:
Hospitals
Ambulatory Surgery Centers
Others
By Region:
North America
Europe
Asia-Pacific
Latin America
Middle East & Africa
We at Aurorawave Intellects Market Report gives total market analysis that suit our customer business need and permit decision maker to run organizations without any problem. We have accomplished greatness in giving start to finish market research arrangements. Our detachment of industry specialists accumulate key data and get ready substance that lines up with our customer's business/specialty.
We at aurorawaveintellects.com offer mainly 3 types of licenses:
• Single User: Research Report copy can be distributed to a single user only
• Multi User: Research Report distribution is restricted up to 5 users.
• Corporate License :Research Report can be distributed across the company.
Based on the nature of the topic or research, the formats vary. The different formats of the report are as following:
• Word Document
• PPT
Following modes are available for making the payment:
• Online Payment (Visa Card, Master Card, Stripe)
• Razorpay
• Net Banking
• Bank Wire Transfer
Our customer service and research specialist team are available by phone and by email. Customer service hours are 24X7 Indian Standard Time (IST). You may reach us at:
• Email: info@aurorawaveintellects.com
• United Kingdom: ++91 7382742511